SCHEMBL3759221

SCHEMBL3759221

CC(C)N(C1CCN(CC(=O)Nc2ccc3c(c2)OC(F)(F)O3)CC1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
LMNA P02545 5/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HSD17B10 Q99714 1/20 0.47
RECQL P46063 1/20 0.47
KDM4E B2RXH2 2/20 0.47
UBE2M P61081 3/20 0.47
DCUN1D1 Q96GG9 3/20 0.47
MAPT P10636 5/20 0.46
TSHR P16473 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
TP53 P04637 1/20 0.43
RORC P51449 1/20 0.43
DRD4 P21917 1/20 0.43
POLB P06746 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485824 0.86 ALDH1A1 (0.52) ALDH1A1LMNASMN1; SMN2HSD17B10RECQL
SCHEMBL3485918 0.85 TSHR (0.56) ALDH1A1LMNASMN1; SMN2HSD17B10KDM4E
SCHEMBL3485705 0.85 ALDH1A1 (0.54) ALDH1A1LMNASMN1; SMN2HSD17B10KDM4E
SCHEMBL3485688 0.85 ALDH1A1 (0.50) ALDH1A1LMNASMN1; SMN2HSD17B10KDM4E
SCHEMBL3485300 0.83 SMN1; SMN2 (0.52) ALDH1A1LMNASMN1; SMN2HSD17B10KDM4E
SCHEMBL3484989 0.83 RORC (0.55) ALDH1A1LMNASMN1; SMN2HSD17B10KDM4E
SCHEMBL3485926 0.83 CACNA1B (0.53) ALDH1A1LMNASMN1; SMN2HSD17B10UBE2M
SCHEMBL3485265 0.81 ALDH1A1 (0.47) ALDH1A1LMNASMN1; SMN2HSD17B10KDM4E
SCHEMBL3485489 0.81 L3MBTL1 (0.51) ALDH1A1LMNASMN1; SMN2HSD17B10UBE2M
SCHEMBL3486183 0.80 LMNA (0.48) ALDH1A1LMNASMN1; SMN2HSD17B10RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765736-B2 Benzenesulfonamide compounds and the use thereof PURDUE PHARMA L.P. (US) 2014-07-01 US claimed
US-20100311792-A1 Benzenesulfonamide Compounds and the Use Thereof PURDUE PHARMA L.P. 2010-12-09 US claimed
US-8765736-B2 Benzenesulfonamide compounds and the use thereof PURDUE PHARMA L.P. (US) 2014-07-01 US disclosed
US-20100311792-A1 Benzenesulfonamide Compounds and the Use Thereof PURDUE PHARMA L.P. 2010-12-09 US disclosed
WO-2009040659-A2 BENZENESULFONAMIDE COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. (DE) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311792-A1 Benzenesulfonamide Compounds and the Use Thereof CACNA1A, CACNA1E, CACNA1B ALDH1A1 1954/4885LMNA 2734/4885SMN1; SMN2 1070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.